Biotop-report 2013

BIOTECON Diagnostics GmbH

BIOTECON Diagnostics was founded in 1998 

and is established as a well-known qualified 

global partner for the food and beverage 

industry as well as for producers of pharma-

ceuticals and cosmetics. 

BIOTECON Diagnostics focuses on develop-

ment, production and marketing of rapid 

detection systems for pathogens, allergens, 

animal species, genetically modified plants 

and beverage spoilage organisms in food, 

feed and other matrices like environmental 

samples. The foodproof

®

, foodproof

®

 SL and 

microproof

®

 Detection and Quantification 

Kits, based on real-time PCR, are developed 

as easy-to-use systems to provide fast, safe 

and specific results for manufacturers and 

consumers. 

Now AOAC and MicroVal validated, 

BIOTECON Diagnostics has offered automat-

ed sample preparation and test setup solu-

tions since 2009. The foodproof

®

 RoboPrep

+

 

Series, a fully automated system for the 

analysis of pathogens, was the first system 

on the market especially designed for the 

needs of the food industry. The foodproof

®

 

RoboPrep Flex offers a convenient and 

robust solution for the automated extraction 

and purification of plant DNA from food and 

feed samples.

BIOTECON Diagnostics additionally offers 

customized contract development and pro-

duction. Due to close contacts with many 

different industries, the company is well 

aware of customers’ current and future chal-

lenges. BIOTECON Diagnostics is thus able 

to provide flexible solutions to production 

and processing companies through new, tai-

lored, and economical approaches.

Address

BIOTECON Diagnostics GmbH

Hermannswerder 17

14473 Potsdam · Germany

Contact

Kornelia Berghof-Jäger, Ph. D. · CEO

Alois Schneiderbauer · CBO

Phone [phone]

Fax 

[phone]

[e-mail]

www.bc-diagnostics.com

43

BioTOPics 46 | September 2013 

BioTOP-Report

BioTeZ Berlin-Buch GmbH

BioTeZ is focused on biotechnological prod-

ucts and services for life science research, 

pharmaceutical industry and diagnostics.

 

In many business fields BioTeZ has own tech-

nologies with outstanding properties, e.g., in 

the sphere of immunoaffinity columns, HRP-

labeling, sundry streptavidin coatings and 

the development of enzyme immunoassays. 

On the basis of many years' experience the 

powerful diagnostic tool recoveryELISA

®

 was 

created for monitoring therapies with bio-

logics. 

Business fields at a glance:

Immunoaffinity chromatography

 

k

Production of customized IAC

 

k

Coupling of different ligands, 

e.g. antibodies against mycotoxins

Premium oligonucleotid synthesis

 

k

DNA / RNA  incl.  modifications

Streptavidin coating

 

k

Microplates and other surfaces and 

materials

 

k

Polystrept R for high binding capacity, 

excellent for lateral flow assays

ELISA development and services

 

k

inclusive conjugate development, 

labeling, purification etc.

Companion Diagnostics

 

k

recoveryELISA

®

 – a  new  diagnostic 

method to predict and to measure inter-

action between therapeutic antibodies or 

biologics and their target molecules. 

Contact

BioTeZ Berlin-Buch GmbH

Robert-Rössle-Straße 10

13125 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail]

www.biotez.de

---

44

BioTOPics 46 | September 2013 

BioTOP-Report

Epigenomics AG

Epigenomics is a molecular diagnostics com-

pany developing and commercializing a 

pipeline of proprietary products for cancer 

diagnosis. The Company’s products enable 

doctors to diagnose cancer earlier and more 

accurately, leading to improved outcomes 

for patients. Epigenomics’ lead product, Epi 

proColon

®

 2.0, is a second generation blood-

based test for the early detection of colorec-

tal cancer, which is currently marketed in 

Europe and has been submitted to the FDA 

for US regulatory approval. 

With clinical studies indicating a majority of 

colorectal cancers are detected with the test 

added to the convenience of a simple blood 

draw, Epi proColon

®

 is expected to improve 

compliance for colorectal cancer screening 

and save lives through early detection of dis-

ease. Laboratory test services based on this 

technology are available in the U.S.A. and 

Canada by our partnering laboratories Quest, 

ARUP, Companion Dx and Gamma Dynacare. 

Epigenomics’ product portfolio further 

includes Epi proLung

®

, a confirmatory test 

aiding in the diagnosis of lung cancer that is 

marketed in Europe, and additional products 

in development for colorectal, lung and 

prostate cancer. The Company’s technology 

and products have been validated through 

multiple partnerships with leading global 

diagnostic companies. Epigenomics is an 

international company with operations in 

Berlin, Germany, and the U.S.A. 

For further information please visit 

www.epigenomics.com

Address 

Epigenomics AG

Kleine Praesidentenstraße 1

10178 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail]

www.epigenomics.com

co.don AG

co.don

®

 AG is a public biopharmaceutical 

company, founded in November 1993, since 

2001 listed on Frankfurt stock exchange. 

co.don

®

 AG manufactures cell-based tissue 

engineering therapeutics of the highest 

purity and to the highest quality standards. 

Its products represent a revolutionary pro-

cess in the biological replacement of dam-

aged articular cartilage and invertebral disc 

by building up strictly autologous tissue 

without the involvement of any external car-

rier materials or additives. The application of 

the products may be minimally invasive or 

arthroscopic and so surgery and rehabilita-

tion times significantly reduced for doctor 

and patient. Because no external materials 

are used, the risks of rejection, inflammation 

and infection are very slight. 

co.don

®

 AG is certified in accordance with 

DIN EN ISO 9001:2008. Furthermore, pro-

duction, quality control and quality assur-

ance have been certified in accordance with 

European Guidelines for Good Manufactur-

ing Practice (EU-GMP) since 1997. In 1997 

co.don

®

 AG was the first biopharmaceutical 

company in Europe to be granted a permit 

for the manufacture of autologous chondro-

cyte and osteoblast transplants under sec-

tion 13 of the German Drugs Law (AMG).

co.don

®

 AG‘s technological, production and 

regulatory expertise makes the company a 

first mover in the market for biological carti-

lage disc tissue replacement and a provider 

of highly effective, safe treatment options 

between pain therapy and endoprothetics.

Address

co.don AG 

Warthestraße21

14513 Teltow · Germany

Contact

Matthias Meißner, M.A.

Head Corporate Communications/IR/PR

Phone [phone] 

Fax 

[phone]

[e-mail] · www.codon.de

---